Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AG019
- Development stage
- Discontinued
- Lead developer
- ActoBio Therapeutics
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies, Recombinant Proteins and Enzymes, Peptides
- Administration
- Oral
01
Overview
AG019 is an investigational oral capsule therapy consisting of genetically modified *Lactococcus lactis* bacteria engineered to deliver human proinsulin (hPINS) and the tolerance-enhancing cytokine human interleukin-10 (hIL-10) directly to the mucosal lining of the gastrointestinal tract. The goal is to induce antigen-specific immune tolerance in patients with type 1 diabetes mellitus (T1D), potentially preserving endogenous insulin production by modulating immune responses against pancreatic beta cells. The drug acts as a microbiome-based gene therapy, combining features of immunotherapy, gene transfer, and bacterial delivery systems. It has been developed primarily for newly diagnosed T1D and has shown safety and tolerability in early-phase clinical trials, both as monotherapy and in combination with teplizumab[2][3][4][5][6][7].
- Other names
- Lactococcus lactis secreting proinsulin and IL-10Lactococcus lactis secreting proinsulin and interleukin-10LL-PINS + interleukin-10LL-PINS+IL-10LL-PINS+hIL10
02
Targets
IL10RA (Interleukin-10 Receptor)Major histocompatibility complex class II-proinsulin peptide complexIL10 (Interleukin-10)
Beyond the preview
Go deeper on AG019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AG019.